BMS-754807

Name: BMS-754807
Brand: Selleck Chemicals
SKU: S1124
Rating: 5 (29 reviews)

For research use only.

Catalog No.S1124

29 publications

CAS No. 1001350-96-4

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Selleck's BMS-754807 has been cited by 29 publications

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2485

PubMed: 31969334 ( click the link to review the publication )

Sci Signal, 2020, 26;13(633):eaba3176

PubMed: 32457113 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Breast Cancer Res Treat, 2020, 10.1007/s10549-020-05927-5

PubMed: 32940848 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3201

PubMed: 31324758 ( click the link to review the publication )

Cell Rep, 2019, 28(12):3224-3237

PubMed: 31533043 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Cytotherapy, 2019, 21(6):619-630

PubMed: 30956007 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1665952

PubMed: 31559898 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Brain Res, 2018, 1678:407-418

PubMed: 29137974 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

Drug Deliv, 2018, 25(1):241-255

PubMed: 29334272 ( click the link to review the publication )

JCI Insight, 2018, 3(8)97398

PubMed: 29669935 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Genes Dev, 2017, 31(6):553-566

PubMed: 28404630 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(11)

PubMed: 29099049 ( click the link to review the publication )
Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(7):1182-96

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Features

Muti-inhibitor of the IGR-1R/IR family.

Targets

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	View More
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	View More

In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). ^[1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. ^[2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	NWTqdGVoU2mwYYPlJIF{e2G7			NVHCfZUycW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDJS2YuOVJiKFnDOVAhRSBzM37NLUBidmRidHjlJIRwf26\|dILlZY0hfGG{Z3X0d{BCc3RiKFnDOVAhRSB{Mn7NLUBidmRiTVHQT{ApUUN3MDC9JFE{dk1r	MYSxPVc4QDB{NB?=
IGF-Sal	MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?			M2HlWmlEPTB;NzDuUS=>	MoH4NVk4PzhyMkS=
CCRF-CEM (ALL)	NFjQWo1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NInwSpZ,PSEQvF2=	MXrEUXNQ	MVfJR\|UxRTFwMkO5JO69VQ>?	MWWxPVk6PjJ5Mh?=
PC3	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlnOglUh\|ryP	M2jtfWROW09?	MXTJR\|UxRTBwOU[1JO69VQ>?	M1;wdFE6QTl4Mkey
JD	MnrIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2PHWJ42KM7:TR?=	NXPwfHllTE2VTx?=	M{fVcmlEPTB;MD6zPVEh\|ryP	M1v2W\|E6QTl4Mkey
DU145	M4LXOmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NX3xS\|E6hjVizszN	MkXhSG1UVw>?	NFvGNW9KSzVyPUGuOFY2KM7:TR?=	Mn\PNVk6QTZ{N{K=
KAG	MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWTEZ2M2hjVizszN	NYLxdpluTE2VTx?=	MlHnTWM2OD1zLk[2OUDPxE1?	NHPDfpIyQTl7NkK3Ni=>
K-562 (CML)	MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWPnUo5zhjVizszN	NGGwbHhFVVOR	M1zuS2lEPTB;Mj6zNFIh\|ryP	Mo\ONVk6QTZ{N{K=
B6-P210 (Murine ALL)	MnLYS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXz+OUDPxE1?	MUHEUXNQ	Mn;zTWM2OD1zLkK5N{DPxE1?	NIDRb2YyQTl7NkK3Ni=>
LN CAP-FGC	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXO4NWJmhjVizszN	MlHtSG1UVw>?	MoHqTWM2OD1zLkSzOEDPxE1?	Ml7oNVk6QTZ{N{K=
VW	NVzjS446T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIDjVpV,PSEQvF2=	NIfT[2JFVVOR	MWjJR\|UxRTBwMEG5JO69VQ>?	Ml\xNVk6QTZ{N{K=
MV411 (B Myelomonocytic)	M1WzNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NH\jToR,PSEQvF2=	MYXEUXNQ	NEjmeFVKSzVyPUCuN\|Mh\|ryP	NVvGZW1GOTl7OU[yO\|I>
MDA-PCa-2b	MUDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1LhfZ42KM7:TR?=	MW\EUXNQ	NFu5OWdKSzVyPUCuNFk5KM7:TR?=	NEi3UXIyQTl7NkK3Ni=>
LG	MlnGS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3\mN542KM7:TR?=	NWDSbXBRTE2VTx?=	MUTJR\|UxRTBwMEO4JO69VQ>?	NWfkXnhsOTl7OU[yO\|I>
RS411 (B cell precursor-ALL)	MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUj+OUDPxE1?	MU\EUXNQ	M{ntWWlEPTB;MD6xNFIh\|ryP	M1e4NlE6QTl4Mkey
22-r-1	NWL0b4pIT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MljuglUh\|ryP	M1SxcGROW09?	NXXlOIZnUUN3ME2wMlE4PSEQvF2=	M{XoRVE6QTl4Mkey
5838	NHq1TlhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MY\+OUDPxE1?	MVrEUXNQ	NYrueppjUUN3ME2wMlA{PCEQvF2=	MV6xPVk6PjJ5Mh?=
P388 (Murine)	NWPpfFRrT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXixfYRyhjVizszN	M4XXV2ROW09?	MV\JR\|UxRTRwMkeg{txO	MX:xPVk6PjJ5Mh?=
A2780/S	NWLF[29WT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NH7oSIV,PSEQvF2=	MV3EUXNQ	NUjBVpdoUUN3ME2wMlEzOiEQvF2=	MmOzNVk6QTZ{N{K=
RDES	NUPRS2hJT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUj+OUDPxE1?	MWPEUXNQ	Mm\xTWM2OD1yLkCxNkDPxE1?	MlHnNVk6QTZ{N{K=
B6-T315I (Murine B-ALL)	NH\vRopIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVK2VGdqhjVizszN	M3HxXGROW09?	MkHUTWM2OD1{LkizJO69VQ>?	NUXycpFzOTl7OU[yO\|I>
TOV 112D	MWDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEfwR2R,PSEQvF2=	MVvEUXNQ	NWi2U5Z6UUN3ME2yMlE1PiEQvF2=	M1;yTVE6QTl4Mkey
TC32	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXHD[FJkhjVizszN	M1ryZ2ROW09?	NWHBWWhUUUN3ME2wMlAxQCEQvF2=	NV\sS\|FlOTl7OU[yO\|I>
HL60 (acute myelocytic)	NVTsZpliT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEPMbWx,PSEQvF2=	NYHZW3A1TE2VTx?=	NVfDfZBUUUN3ME2wMlEzKM7:TR?=	NV;IN2pLOTl7OU[yO\|I>
TOV 21G	NIPsT\|dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnfYglUh\|ryP	M2fOTmROW09?	MmPFTWM2OD12LkK3PUDPxE1?	NEfMcHcyQTl7NkK3Ni=>
TC71	MlzDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGnlVpd,PSEQvF2=	MWfEUXNQ	M1PrbWlEPTB;MD6wNVQh\|ryP	MWqxPVk6PjJ5Mh?=
HPN-ALL (T-cell)	M3nTU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXjYdIU2hjVizszN	Mlj2SG1UVw>?	NXXFXVZUUUN3ME2wMlUzKM7:TR?=	M4GzU\|E6QTl4Mkey
A2780R	NWHmfXN[T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUf+OUDPxE1?	MV7EUXNQ	M2q3emlEPTB;MT61OlQh\|ryP	M4\qfVE6QTl4Mkey
Rh1	NV[4T\|R1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXT+OUDPxE1?	M1jtV2ROW09?	MmCzTWM2OD1yLkCyO{DPxE1?	MnXjNVk6QTZ{N{K=
Kasumi-1 (acute myeloid)	Ml\3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXn+OUDPxE1?	MXTEUXNQ	M2K4emlEPTB;MD6xOkDPxE1?	MlfkNVk6QTZ{N{K=
sk-ov-3	NGToTWhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{O5UZ42KM7:TR?=	M{nrdmROW09?	M2nLUGlEPTB;NT6xJO69VQ>?	MV2xPVk6PjJ5Mh?=
ME	NV\4VYhDT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVX+OUDPxE1?	NWC5U2RMTE2VTx?=	M2TvS2lEPTB;MD6wNVUh\|ryP	M1vKfVE6QTl4Mkey
L1210 (Murine lymphocytic)	MoH1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MojHglUh\|ryP	MoLvSG1UVw>?	MWjJR\|UxRTJwM{mg{txO	NXT3XpJwOTl7OU[yO\|I>
sw-626	NETlfXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmK5glUh\|ryP	MonPSG1UVw>?	M3r5O2lEPTB;Mj6zNFYh\|ryP	MUCxPVk6PjJ5Mh?=
CTR	MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVLnOolXhjVizszN	MVXEUXNQ	NFXzSIVKSzVyPUCuNlU{KM7:TR?=	M4DaZ\|E6QTl4Mkey
ML2 (Myelomonocytic)	NX;tVVB7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUH+OUDPxE1?	M4r4VGROW09?	Mmq0TWM2OD1yLkC5JO69VQ>?	MnT4NVk6QTZ{N{K=
ovcar-3	NYnJbXNHT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIDnN3J,PSEQvF2=	MmfVSG1UVw>?	Ml\nTWM2OD13IN88US=>	NHPYZowyQTl7NkK3Ni=>
Rh36	NGnFdFJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3O0O542KM7:TR?=	NUO4e4NCTE2VTx?=	NXz4R3F6UUN3ME2xMlQ{OiEQvF2=	NVn6UHhzOTl7OU[yO\|I>
MOLM-13 (acute myeloid)	NETIbpFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYP4Z5dxhjVizszN	MlHvSG1UVw>?	Mn75TWM2OD1yLkSyJO69VQ>?	NVnnVJhMOTl7OU[yO\|I>
ovcar-4	MofRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUj+OUDPxE1?	NIHjZpNFVVOR	NXOzSJMyUUN3ME2xJO69VQ>?	M3[0UFE6QTl4Mkey
Rh41	M{DTWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVT+OUDPxE1?	MULEUXNQ	M1j0bWlEPTB;MD6wNFUh\|ryP	MnTRNVk6QTZ{N{K=
Mutz 2 (acute myeloid)	MkfVS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoPJglUh\|ryP	NFfzendFVVOR	M3\CVmlEPTB;MT6xOUDPxE1?	NHXJPZkyQTl7NkK3Ni=>
ovcar-5	Mkj2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIn1SXB,PSEQvF2=	MmPjSG1UVw>?	NUn1S5BjUUN3ME2wMlA2KM7:TR?=	M2PQ[VE6QTl4Mkey
RD1	NYXr[JRST3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NH\IWHh,PSEQvF2=	NXTmbnczTE2VTx?=	Mn;STWM2OD1yLkC2PEDPxE1?	MnzaNVk6QTZ{N{K=
OCI-AML 2 (acute myeloid)	MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVL+OUDPxE1?	Mo\WSG1UVw>?	NHvvVFFKSzVyPUOuN\|Mh\|ryP	NFPjVoEyQTl7NkK3Ni=>
786-O	NEPnbHZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2T1bp42KM7:TR?=	MUfEUXNQ	M3iwemlEPTB;MT62OFch\|ryP	NHjWUWIyQTl7NkK3Ni=>
A673	NEj6PIhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGTYSYZ,PSEQvF2=	M1PscGROW09?	MVnJR\|UxRTBwNEC4JO69VQ>?	MW[xPVk6PjJ5Mh?=
TALL-1 (T-cell)	NU[wcnFTT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NG\MWFd,PSEQvF2=	M13UbWROW09?	NVPnb2tXUUN3ME2xMlI5KM7:TR?=	MXOxPVk6PjJ5Mh?=
151-B	MkHoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NX[1VJA1hjVizszN	MmnZSG1UVw>?	NV\kcYVIUUN3ME2yMlY4KM7:TR?=	MoDxNVk6QTZ{N{K=
PFSK-1	NH3sOoxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVfKT5dYhjVizszN	NEPoUHhFVVOR	M3\MOmlEPTB;MD6xN\|Ih\|ryP	Ml3rNVk6QTZ{N{K=
THP-1	NWn1NZJNT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVz+OUDPxE1?	NV3SNWJETE2VTx?=	MkjZTWM2OD14LkW4JO69VQ>?	MWCxPVk6PjJ5Mh?=
HEK293	Mme2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MkHoglUh\|ryP	M4X2[GROW09?	M3P3Z2lEPTB;MD65NVUh\|ryP	M2XrNFE6QTl4Mkey
DAOY	NIft[mRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3;MSp42KM7:TR?=	MYfEUXNQ	MVfJR\|UxRTFwOUe5JO69VQ>?	NF\UeIgyQTl7NkK3Ni=>
SET2	M3\yWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFPqfnF,PSEQvF2=	NXzKSJRFTE2VTx?=	M2nFVmlEPTB;MD6yPVgh\|ryP	NHq4ZWsyQTl7NkK3Ni=>
HTB-46	MknpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2riNZ42KM7:TR?=	NWHlfXY3TE2VTx?=	MUTJR\|UxRTVwMkWg{txO	M1PZ[lE6QTl4Mkey
SK-NAS	MnfFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NV\5b3JQhjVizszN	MYTEUXNQ	NHq0SldKSzVyPUCuOFk4KM7:TR?=	MV6xPVk6PjJ5Mh?=
CTLL2	M2n1Xmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXj+OUDPxE1?	MnjOSG1UVw>?	NXTSWFgxUUN3ME6xMlAxKM7:TR?=	NE\T[ZkyQTl7NkK3Ni=>
HTB-47	MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYT+OUDPxE1?	NFrNUlRFVVOR	MmLkTWM2OD1{LkC1OkDPxE1?	MXGxPVk6PjJ5Mh?=
LAN-1	NWHkTZA2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MWD+OUDPxE1?	NYDT[4JVTE2VTx?=	NHvXcYZKSzVyPUCuNFQh\|ryP	M2TkO\|E6QTl4Mkey
ST486	M{LPOmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVz+OUDPxE1?	M2S0[WROW09?	MoLOTWM2OD1zLkG5JO69VQ>?	M1TqTVE6QTl4Mkey
HS766T	NYrHWFRQT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGP5ZYJ,PSEQvF2=	NXXTcJd1TE2VTx?=	NG\wSW9KSzVyPUKuNFAyKM7:TR?=	M3vUUFE6QTl4Mkey
IMR-32	M3rqRWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHPYWm1,PSEQvF2=	M3PSRmROW09?	MVXJR\|UxRTBwMk[xJO69VQ>?	MVGxPVk6PjJ5Mh?=
Daudi (Burkitt's)	M2jjSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFP2XHN,PSEQvF2=	NGfkVVFFVVOR	MX;JR\|UxRTJwNkO3JO69VQ>?	M3PrNVE6QTl4Mkey
Aspc-1	M4SzXmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4TzeZ42KM7:TR?=	NXjvPY1jTE2VTx?=	M4\BWmlEPTB;MD6zO\|kh\|ryP	M4jQSVE6QTl4Mkey
SK-NSH	NGnZe\|JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2jDOp42KM7:TR?=	M1j6cGROW09?	NIfPWYlKSzVyPUCuNVM6KM7:TR?=	MYSxPVk6PjJ5Mh?=
MEC-1 (Chronic B cell)	M{HuT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVn+OUDPxE1?	M3rR[WROW09?	M{njfWlEPTB;Mj62N\|ch\|ryP	NXfwUGZOOTl7OU[yO\|I>
Capan-2	M4\JR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MlPZglUh\|ryP	M1PoXWROW09?	NVrD[WFFUUN3ME2xMlc4PCEQvF2=	M13Mb\|E6QTl4Mkey
SHSY5Y	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NHO0UIl,PSEQvF2=	M3ThUGROW09?	Mk\hTWM2OD1yLkGwOkDPxE1?	MXyxPVk6PjJ5Mh?=
U937 (Histioocytic)	NWDvRnhqT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFXRVHN,PSEQvF2=	M4PaeWROW09?	M2q4S2lEPTB-NT6wNEDPxE1?	NFT4docyQTl7NkK3Ni=>
Bxpc-1	M1\iR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYH+OUDPxE1?	NWLVWZFVTE2VTx?=	NIi5W4lKSzVyPUGuPVI1KM7:TR?=	M1zoS\|E6QTl4Mkey
Bxpc-3	NHS5ZXNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYH+OUDPxE1?	NFnQcmZFVVOR	M{[ye2lEPTB-NT6wNEDPxE1?	MmW5NVk6QTZ{N{K=
HTB-92	MnfSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnriglUh\|ryP	MYTEUXNQ	Mne3TWM2OD1zLkCyJO69VQ>?	NYCzclA4OTl7OU[yO\|I>
OCI-LY10 (B-cell)	MVzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWS5WopChjVizszN	NF6w[pFFVVOR	M4XRPWlEPTB;MD60OUDPxE1?	MX2xPVk6PjJ5Mh?=
PANC-1	M4PvTWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoX4glUh\|ryP	NHPjbmdFVVOR	NUT3VmNFUUN3ME61MlAxKM7:TR?=	MU[xPVk6PjJ5Mh?=
To184.T	MkHSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2nN[p42KM7:TR?=	MlnaSG1UVw>?	NVHrc2hjUUN3ME2wMlQ3QSEQvF2=	MUKxPVk6PjJ5Mh?=
OCI-LY19 (B-cell)	M4XwOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXT+OUDPxE1?	NHHHRmhFVVOR	NWn6UFNvUUN3ME2wMlQh\|ryP	MVyxPVk6PjJ5Mh?=
PANC-1 BM	MmrQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1Tqep42KM7:TR?=	M3TtcmROW09?	MmP2TWM2OD53LkCwJO69VQ>?	M3HaUVE6QTl4Mkey
SA-4	MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXH+OUDPxE1?	M{PWcmROW09?	NIfoPFhKSzVyPUGuN\|AyKM7:TR?=	MVexPVk6PjJ5Mh?=
RPMI 8226	NFnPfZpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Moi5glUh\|ryP	NXjWO2N7TE2VTx?=	MlLPTWM2OD1zLkK5N{DPxE1?	MY[xPVk6PjJ5Mh?=
HPAF-II	NUTxblFkT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYrCd5I{hjVizszN	M2fhOWROW09?	NIDMZ3lKSzVyPUCuOlQ1KM7:TR?=	MmjRNVk6QTZ{N{K=
SHP-77	NIPaR2lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1m0Rp42KM7:TR?=	MWLEUXNQ	NULhVHBYUUN3ME2xMlg5QCEQvF2=	NYnvUVNUOTl7OU[yO\|I>
U266 B1	M4TqTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M{XuUp42KM7:TR?=	M3XJNWROW09?	NEHofmlKSzVyPUGuOlY6KM7:TR?=	MXmxPVk6PjJ5Mh?=
Hs700t	MkXsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUD+OUDPxE1?	NIC1O5hFVVOR	NGG3PGZKSzVyPUCuNlMyKM7:TR?=	MUixPVk6PjJ5Mh?=
NCI-446	MlPCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGTrfG1,PSEQvF2=	NF6y[HBFVVOR	NXGzT4p7UUN3ME2xMlE2PCEQvF2=	NY\reG9yOTl7OU[yO\|I>
H929	MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4TpT542KM7:TR?=	NFLYU2NFVVOR	MUfJR\|UxRTBwMEG0JO69VQ>?	MlnSNVk6QTZ{N{K=
PL45	NFXocIFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEL5XIh,PSEQvF2=	NFG0UYhFVVOR	MVXJR\|UxRTJwMkW1JO69VQ>?	MnjVNVk6QTZ{N{K=
NCI-H383	NH3PUodIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVL+OUDPxE1?	MVTEUXNQ	M2XWZ2lEPTB-NT6wNEDPxE1?	NXnJdlN4OTl7OU[yO\|I>
JJN3	NYjIdZd6T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXH+OUDPxE1?	MmDESG1UVw>?	NFO5boVKSzVyPUKuOFM{KM7:TR?=	M4nMflE6QTl4Mkey
SU.86.86	MkC0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mn\tglUh\|ryP	MXHEUXNQ	NIj0b5dKSzVyPUKuOlczKM7:TR?=	NUnuW5NqOTl7OU[yO\|I>
H1299	MkfFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MlnkglUh\|ryP	MlOySG1UVw>?	NX:wS21KUUN3ME61MlAxKM7:TR?=	MVyxPVk6PjJ5Mh?=
MDA-MB-468	M3O3fGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NELIepF,PSEQvF2=	MUPEUXNQ	MljITWM2OD1yLkWwOEDPxE1?	MlzlNVk6QTZ{N{K=
SW1990	NXXt[YV{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3vHZZ42KM7:TR?=	M2fWWGROW09?	NVfOXGhCUUN3ME2wMlgzPiEQvF2=	M3rifFE6QTl4Mkey
Calu-6	MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGi3TJp,PSEQvF2=	M3PLPWROW09?	NXPJXmlKUUN3ME61MlAxKM7:TR?=	MonWNVk6QTZ{N{K=
MDA-MB-231	MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYeyT5RVhjVizszN	NHXIVZhFVVOR	M{ixfWlEPTB;MT62OFgh\|ryP	M{KyfVE6QTl4Mkey
SW-684	MkLHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGrvdXd,PSEQvF2=	NV\qbZhvTE2VTx?=	MXrJR\|UxRjVwMECg{txO	NEfaRmYyQTl7NkK3Ni=>
H209	M3\RfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1L5Tp42KM7:TR?=	MmKxSG1UVw>?	MYHJR\|UxRTFwMUmzJO69VQ>?	NHfKZW8yQTl7NkK3Ni=>
MDA-MB-231T	NWXSWIJVT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NF75[VZ,PSEQvF2=	NWDQO\|lUTE2VTx?=	NH;YZYZKSzVyPkWuNFAh\|ryP	NYHKe\|J{OTl7OU[yO\|I>
HT1080/S	NX;MSIVCT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2r0N542KM7:TR?=	M4XId2ROW09?	Mln3TWM2OD1yLkWzNUDPxE1?	MXexPVk6PjJ5Mh?=
H526 0.044	M3P1R2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoLsglUh\|ryP	M{jjZ2ROW09?	Moq3TWM2OD1yLkC0OEDPxE1?	M3rI[\|E6QTl4Mkey
DU4475 2.431	M130Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVr0bWs5hjVizszN	Mle2SG1UVw>?	NFT2TJhKSzVyPUKuOFMyKM7:TR?=	MlL4NVk6QTZ{N{K=
HCT116	NIDXV3JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXHFRW5HhjVizszN	Mk[0SG1UVw>?	NHvRXm9KSzVyPUCuPFUzKM7:TR?=	NXLYeGI{OTl7OU[yO\|I>
M109	NGXJelZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUnEcWw6hjVizszN	NVjTU3RyTE2VTx?=	Mo\QTWM2OD1zLkC1OUDPxE1?	NVHNSGhXOTl7OU[yO\|I>
BT549	NGjrdWVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYLIUoJ4hjVizszN	NF7oeZZFVVOR	M17rV2lEPTB;MT62OFUh\|ryP	NWPsV4xtOTl7OU[yO\|I>
HCT116/VM46	NX3PdIFjT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1jnb542KM7:TR?=	NHTmNY5FVVOR	NYnLXWRwUUN3ME2xMlcxOiEQvF2=	MmfaNVk6QTZ{N{K=
H460	MmLyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MorhglUh\|ryP	MWnEUXNQ	MWfJR\|UxRTBwN{m1JO69VQ>?	NHfwd5MyQTl7NkK3Ni=>
MCF-7	MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUT+OUDPxE1?	MUjEUXNQ	M3HTTmlEPTB;MD6wNVYh\|ryP	NHjKTpMyQTl7NkK3Ni=>
GEO	NWPPdYtTT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2DnWp42KM7:TR?=	M3TqV2ROW09?	M2HKcGlEPTB;MD6zOVYh\|ryP	MUOxPVk6PjJ5Mh?=
H441 0.646	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3nVVZ42KM7:TR?=	MU\EUXNQ	NWPzV5doUUN3ME2wMlY1PiEQvF2=	MnvHNVk6QTZ{N{K=
MCF-7-807R	NX3UXXhZT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2jYV542KM7:TR?=	NYixTYI1TE2VTx?=	NXHtV45wUUN3ME2wMlQ6KM7:TR?=	M1TCelE6QTl4Mkey
Colo205	NVLWelE6T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3jwTZ42KM7:TR?=	MWfEUXNQ	NWTvXnl4UUN3ME2wMlExPCEQvF2=	NFmyOnMyQTl7NkK3Ni=>
H292	NYe4[2Y1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWHyWlg6hjVizszN	M1TGSGROW09?	MojYTWM2OD1yLke4PEDPxE1?	NXX6bIFJOTl7OU[yO\|I>
BT474 (S)	MnnmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NEnvWXV,PSEQvF2=	MVzEUXNQ	NIHKZnpKSzVyPUKuOFA{KM7:TR?=	MlXiNVk6QTZ{N{K=
HT-29	Mn;KS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFT2fId,PSEQvF2=	Mkn2SG1UVw>?	M{\6R2lEPTB;Mj6xNFMh\|ryP	M3uycFE6QTl4Mkey
A549	NXTrfVY1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX7+OUDPxE1?	Ml21SG1UVw>?	NED3bpVKSzVyPUCuOlc2KM7:TR?=	MUixPVk6PjJ5Mh?=
BT474-M1	NFTX[WlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVn+OUDPxE1?	M37BbmROW09?	MnTBTWM2OD1{LkO2OUDPxE1?	MWWxPVk6PjJ5Mh?=
SW480	M4LM[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVn+OUDPxE1?	MUHEUXNQ	MnrMTWM2OD53LkCwJO69VQ>?	M3LVfFE6QTl4Mkey
L2987	M2rhUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3HRe542KM7:TR?=	M1G3N2ROW09?	NG\OZW9KSzVyPUCuOFQzKM7:TR?=	M1\sSVE6QTl4Mkey
AU565	MoDGS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M{[0b542KM7:TR?=	NHXKOYJFVVOR	NHWxd5BKSzVyPUSuPVch\|ryP	M1G3TVE6QTl4Mkey
SW403	NEXvenJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmfaglUh\|ryP	M2LJR2ROW09?	NGjQUIlKSzVyPUCuNlIh\|ryP	NXjEO2F7OTl7OU[yO\|I>
H1437	MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NU\vXXh5hjVizszN	MoPnSG1UVw>?	MYPJR\|UxRTBwNUKzJO69VQ>?	NH3VUYYyQTl7NkK3Ni=>
BT-20	M1Ozcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2DZeJ42KM7:TR?=	Mk\hSG1UVw>?	M133XWlEPTB;Mz61OlIh\|ryP	NFrrTm0yQTl7NkK3Ni=>
Colo320HSR	NUXZdoU5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NH7RcW9,PSEQvF2=	M{XWRWROW09?	M{jGe2lEPTB;MD6wNVEh\|ryP	NHXuXWkyQTl7NkK3Ni=>
H2087	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFq5XZd,PSEQvF2=	MoPNSG1UVw>?	NW\CS\|l5UUN3ME6xMlAxKM7:TR?=	MXexPVk6PjJ5Mh?=
HCC1419	NGryS4RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M13Lep42KM7:TR?=	MYfEUXNQ	M1Xo[2lEPTB;Mj61NVch\|ryP	NFL5XpEyQTl7NkK3Ni=>
WiDr	NGmwWGhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHTyZ\|V,PSEQvF2=	M4nqS2ROW09?	MnP3TWM2OD1yLkC3OkDPxE1?	NELB[XEyQTl7NkK3Ni=>
H661 0.573	M2\V[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXLiOGR{hjVizszN	NFnu[ZFFVVOR	MoOyTWM2OD1yLkW3N{DPxE1?	MmiyNVk6QTZ{N{K=
HCC-38	MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWfH[ZVshjVizszN	NHflOVJFVVOR	Mm\QTWM2OD53LkCwJO69VQ>?	NYLy[lVvOTl7OU[yO\|I>
LS174T	NHPUbWRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYraSolPhjVizszN	NWHBSVFoTE2VTx?=	M3HVWWlEPTB;MD61N\|Uh\|ryP	NELvcYgyQTl7NkK3Ni=>
H211	M{XyTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MWf+OUDPxE1?	NFzCXZJFVVOR	NHvxV2VKSzVyPUCuO\|M{KM7:TR?=	MWSxPVk6PjJ5Mh?=
HCC70	NHjNdYNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{DhVZ42KM7:TR?=	NVT5N3lITE2VTx?=	NFezSVhKSzVyPUGuOVUh\|ryP	MXWxPVk6PjJ5Mh?=
SW116	Mlz0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MkLxglUh\|ryP	NG\JcIpFVVOR	MnuxTWM2OD1yLkC2O{DPxE1?	MnHGNVk6QTZ{N{K=
H513	MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFvLW3h,PSEQvF2=	M1XKdGROW09?	NILaSWJKSzVyPUSuOFQ5KM7:TR?=	NI\yS3kyQTl7NkK3Ni=>
MDA-MB-157	NGH6fYhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MkfiglUh\|ryP	M1PIUmROW09?	MWnJR\|UxRTBwMEO2JO69VQ>?	MWOxPVk6PjJ5Mh?=
H2052	M2rwdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NICze5N,PSEQvF2=	NYH1NZA5TE2VTx?=	MX7JR\|UxRTFwMEWg{txO	NVTpSYlPOTl7OU[yO\|I>
MDA-MB-415	NHTsPXRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWC5WVhShjVizszN	MXnEUXNQ	MUPJR\|UxRjVwMECg{txO	M3PTb\|E6QTl4Mkey
DLD-1	MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFvlfGJ,PSEQvF2=	NYnY[2tNTE2VTx?=	MlPYTWM2OD1yLkmwPUDPxE1?	MUKxPVk6PjJ5Mh?=
H2595	M1LVOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3zEOp42KM7:TR?=	MkDKSG1UVw>?	MX7JR\|UxRTRwNEe1JO69VQ>?	NESwNVAyQTl7NkK3Ni=>
MDA-MB-435S	M3viT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYX+OUDPxE1?	NVPQVWFSTE2VTx?=	NUfKUHNwUUN3ME2xMlg3QSEQvF2=	MXGxPVk6PjJ5Mh?=
HCT15	M2DXU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYP+OUDPxE1?	NHjySGlFVVOR	NIjG[4RKSzVyPkGuNFAh\|ryP	NGmxV5kyQTl7NkK3Ni=>
SK-Hep1	M4faPWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFjFfZV,PSEQvF2=	MlTySG1UVw>?	NEHjZnFKSzVyPUCuNVQ3KM7:TR?=	M1GzSFE6QTl4Mkey
MDA-MB-436	MkPxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXP+OUDPxE1?	M17WcmROW09?	M3TOU2lEPTB;NT61NFIh\|ryP	MoDSNVk6QTZ{N{K=
KM12C	M4jiR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVX+OUDPxE1?	MV\EUXNQ	Mk\WTWM2OD1yLkC1OEDPxE1?	NX3WbpZSOTl7OU[yO\|I>
HEPG2	MmjLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnvhglUh\|ryP	M4PLZmROW09?	Mln6TWM2OD1yLkCyOUDPxE1?	MVmxPVk6PjJ5Mh?=
MDA-MB-453	M1jGWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NGnEcJh,PSEQvF2=	Mn;3SG1UVw>?	NU\x[nR6UUN3ME2xMlg3QSEQvF2=	NUHVWmFqOTl7OU[yO\|I>
KM12SM	MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFi1b2R,PSEQvF2=	NX7rUHVpTE2VTx?=	NX3VRopxUUN3ME2wMlA2QSEQvF2=	NHW5Z3MyQTl7NkK3Ni=>
1483	NFHoTpNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnfBglUh\|ryP	M3rkeGROW09?	NGr6dGJKSzVyPUKuNVkh\|ryP	Mn;kNVk6QTZ{N{K=
Hs578t	MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MoDpglUh\|ryP	MYjEUXNQ	M{fyVmlEPTB;MT6yPFch\|ryP	M{CzOlE6QTl4Mkey
LS180	MknqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXr+OUDPxE1?	NVzsWJJITE2VTx?=	NEHSU3BKSzVyPUCuOlk3KM7:TR?=	MoH1NVk6QTZ{N{K=
FaDu	MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MorYglUh\|ryP	NWDRZo9mTE2VTx?=	M3SxUGlEPTB;MT6yO{DPxE1?	MUSxPVk6PjJ5Mh?=
ZR-75-1	NY\kVmxWT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MlrkglUh\|ryP	MWPEUXNQ	MYTJR\|UxRTJwMEi0JO69VQ>?	MVmxPVk6PjJ5Mh?=
LS513	Ml3BS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYD+OUDPxE1?	MmL2SG1UVw>?	NXyySYxMUUN3ME2wMlE{PSEQvF2=	NF\Nc2wyQTl7NkK3Ni=>
Detroit.562	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXnlfm1HhjVizszN	NIriXZhFVVOR	MWPJR\|UxRTFwMUSg{txO	MV[xPVk6PjJ5Mh?=
ZR-75-30	M{[5Smdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVLuTJVOhjVizszN	M{Ptc2ROW09?	NFW1e3hKSzVyPkWuNFAh\|ryP	M3Xo[lE6QTl4Mkey
RKO-PM	NWT3SJU2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmTGglUh\|ryP	NFTKVpZFVVOR	MXjJR\|UxRTBwMkOyJO69VQ>?	M1PBTVE6QTl4Mkey
Cal.27	MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3HkbJ42KM7:TR?=	MX7EUXNQ	MULJR\|UxRTJizszN	NWnyUmhCOTl7OU[yO\|I>
KPL4	NXmwXHdoT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3nLSJ42KM7:TR?=	M4\Ue2ROW09?	MYHJR\|UxRTFwMkWyJO69VQ>?	M3S0[FE6QTl4Mkey
PKO-RM13	NXTxbIpET3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MknyglUh\|ryP	M13OSGROW09?	NHLMUWlKSzVyPUCuOFI2KM7:TR?=	MUixPVk6PjJ5Mh?=
HS.53.T	MnvFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHj5dlZ,PSEQvF2=	NILw[m1FVVOR	MoLoTWM2OD1yLke5JO69VQ>?	MoPtNVk6QTZ{N{K=
EMT6	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXH+OUDPxE1?	MV3EUXNQ	NIrHSlNKSzVyPUCuPFA3KM7:TR?=	NV3rWVdzOTl7OU[yO\|I>
SNU-C1	NXXvNFhxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M332SZ42KM7:TR?=	MnnXSG1UVw>?	MnLVTWM2OD1yLkCwO{DPxE1?	NGfCOXcyQTl7NkK3Ni=>
SQCCY1	NVnpT\|k{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkfkglUh\|ryP	NEC2O\|BFVVOR	MV7JR\|UxRTBwN{mg{txO	M{i1[\|E6QTl4Mkey
SW480	NYfsZm1YT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1u5NJ42KM7:TR?=	M2XHdmROW09?	MVPJR\|UxRTBwMEO3JO69VQ>?	MYSxPVk6PjJ5Mh?=
SCC9	M2TYdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVXKb3NHhjVizszN	NUSyS4dkTE2VTx?=	NHH2bHhKSzVyPUCuO\|Uh\|ryP	NUjhWG5IOTl7OU[yO\|I>
SK-LMS-1	Mk\6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1zs[542KM7:TR?=	MYLEUXNQ	M4H3e2lEPTB;MD62PFch\|ryP	MUOxPVk6PjJ5Mh?=
SCC25	NF;uSFlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Ml63glUh\|ryP	M2nmS2ROW09?	M1nmbWlEPTB;MD62PEDPxE1?	MWmxPVk6PjJ5Mh?=
U87	M4OxTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVj+OUDPxE1?	NGqxbWlFVVOR	MVTJR\|UxRTBwOUWg{txO	NVu0OlhjOTl7OU[yO\|I>
SCC15	MlTRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mn7YglUh\|ryP	NWTTV4VuTE2VTx?=	MoDOTWM2OD1yLk[3JO69VQ>?	MXSxPVk6PjJ5Mh?=
T98G	MmK0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX\+OUDPxE1?	NWHucFJmTE2VTx?=	NWnKTmZHUUN3ME2xMlIyQCEQvF2=	M2XKPVE6QTl4Mkey
SCC4	NFq2WItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFP1NJh,PSEQvF2=	MVHEUXNQ	MmHtTWM2OD1yLk[zJO69VQ>?	M4q1NlE6QTl4Mkey
U118	NFjzPXBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGW2SW5,PSEQvF2=	M4jwUmROW09?	NXPkR2oyUUN3ME2xMlYyQCEQvF2=	NIS2WmcyQTl7NkK3Ni=>
TU167	MmjUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFPjSGZ,PSEQvF2=	NGXXU5JFVVOR	NW\zUmp{UUN3ME20MlUzKM7:TR?=	MUKxPVk6PjJ5Mh?=
NCI-H727	MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MmG0glEx6oDMzszN	MV7EUXNQ	MX\JR\|UxRTR{ODDuUS=>	NF\xSYczODN6NUe0Oy=>
NCI-H720	M1jUUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFzUN4t,OTEkgJtOwG0>	M3;lcGROW09?	M4PsO2lEPTB;Mj64JO69VQ>?	NYjjWXN{OjB\|OEW3OFc>
NCI-H835	MnfRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXe4R5p6hjFy4pEK{txO	M2KxVGROW09?	NInwWlhKSzVyPUGg{txO	NEDLS4YzODN6NUe0Oy=>
NCI-H727	NHn4PW1McW6jc3WgZZN{[Xl?	M3HTWZ4yOOLCit88US=>	NEflTplFVVOR	NFy1VYpqdmirYnn0d{Bkd26\|dHn0eZRqfmViSVfGNXIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	M4DFb\|IxOzh3N{S3
RD	NVrGSolrT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUH+NVDjiIsQvF2=		M1voUWlEPTB;MT6xNkDDvU1?	NFfa[YUzOTJ7OEe0OS=>
Rh41	MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEXmcFh,OTEkgJtOwG0>		NGT2ZoRKSzVyPUCuNFchyrWP	MYOyNVI6QDd2NR?=
Rh18	M17BV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NEfYN3N,OTEkgJtOwG0>		NGS1dlJKSzVyPUSuPVYhyrWP	MWmyNVI6QDd2NR?=
Rh30	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MoDCglEx6oDMzszN		MYrJR\|UxRTBwMUmgxtVO	M2TFT\|IyOjl6N{S1
BT-12	NYfjPIJ7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWq5W3RGhjFy4pEK{txO		NFP3ZnJKSzVyPUCuO\|ghyrWP	MVmyNVI6QDd2NR?=
CHLA-266	MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWfEOGtDhjFy4pEK{txO		Mo\1TWM2OD1yLki5JOK2VQ>?	MkDhNlEzQTh5NEW=
TC-71	MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGfZNGZ,OTEkgJtOwG0>		NWPQW5J{UUN3ME2wMlEyKML3TR?=	M3u2O\|IyOjl6N{S1
CHLA-9	Mmf3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1X6NZ4yOOLCit88US=>		NX\WXmVFUUN3ME2wMlEzKML3TR?=	NESy[4ozOTJ7OEe0OS=>
CHLA-10	M2L3[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmP3glEx6oDMzszN		MmjtTWM2OD1yLk[yJOK2VQ>?	MkPqNlEzQTh5NEW=
CHLA-258	NXjndVh5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2naVp4yOOLCit88US=>		NGPuTmdKSzVyPUCuNlchyrWP	NGi5UIozOTJ7OEe0OS=>
GBM2	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYm3XIxEhjFy4pEK{txO		M3Xx[WlEPTB;MT60O{DDvU1?	MnHiNlEzQTh5NEW=
NB-1643	MnTsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mo\pglEx6oDMzszN		M4X3RWlEPTB;MD6xNkDDvU1?	NU\WVll4OjF{OUi3OFU>
NB-EBc1	NHnscZJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEn4OWt,OTEkgJtOwG0>		NFHWb4tKSzVyPUCuN\|UhyrWP	NF72SI4zOTJ7OEe0OS=>
CHLA-90	NH61T\|JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnuzglEx6oDMzszN		NUfoUJdSUUN3ME2wMlc4KML3TR?=	NUDDZ5VWOjF{OUi3OFU>
CHLA-136	NXyyOIlmT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVHhNJJuhjFy4pEK{txO		M3XHOmlEPTB;MD61NkDDvU1?	M3rkT\|IyOjl6N{S1
NALM-6	M1fiUWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NG\iUYJ,OTEkgJtOwG0>		M1XHOGlEPTB;MD60PUDDvU1?	M3\5NVIyOjl6N{S1
COG-LL-317	M3jqcWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoPGglEx6oDMzszN		M13XOWlEPTB;MT6zPEDDvU1?	MoDHNlEzQTh5NEW=
RS4;11	M2rQfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoPlglEx6oDMzszN		NUH2PWx5UUN3ME2wMlM5KML3TR?=	M2fyOlIyOjl6N{S1
MOLT-4	MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NH7WVJF,OTEkgJtOwG0>		MoXyTWM2OD1yLkWzJOK2VQ>?	M1rGSVIyOjl6N{S1
CCRF-CEM	NEOyemhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnfSglEx6oDMzszN		NXTVT2ZsUUN3ME2xMlE{KML3TR?=	MkTnNlEzQTh5NEW=
Kasumi-1	MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NX\rb5JVhjFy4pEK{txO		MWTJR\|UxRTFwMjFCuW0>	MUeyNVI6QDd2NR?=
Karpas-299	M4LZfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkfxglEx6oDMzszN		NIi3[VlKSzVyPUGuOlQhyrWP	Ml\ENlEzQTh5NEW=
Ramos-RA1	MnHOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NF;CRlN,OTEkgJtOwG0>		NU\SNmZ5UUN3ME2xMlMyKML3TR?=	NYXQXppLOjF{OUi3OFU>
Rh30	NEnt[ldHfW6ldHnvckBie3OjeR?=			NF\pZlZqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:\|cHjvdplt[XSrb36=	MUSyOVkzPTN5OB?=
Rh41	NIPPbIRHfW6ldHnvckBie3OjeR?=			MnWxbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w	NIDrSY0zPTl{NUO3PC=>
RD	MnzCSpVv[3Srb36gZZN{[Xl?			NUjRNGRCcW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u	Ml\VNlU6OjV\|N{i=
A549	MnLvT4lv[XOnIHHzd4F6	NUPkRmZ5OC534pEK{txO	M{L0e2ROW09?	NYW5RWoxcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25?	MofFNlY6Ojh3N{i=
NCI-H358	MYLLbY5ie2ViYYPzZZk>	NXX6Zog1OC534pEK{txO	MoTrSG1UVw>?	NGO1Z25qdmirYnn0d{BKT0ZvSWKvTXIh[WO2aY\heIlwdg>?	M1vEflI3QTJ6NUe4
A549	NXzCc29MTnWwY4Tpc44h[XO\|YYm=	NUP4NWNyOC534pEK{txO	NGLJW2pFVVOR	NWTKcmJl[2G3c3XzJIEh[2:wY4XydoVvfCCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgZY5lKEWUSx?=	M1;sfVI3QTJ6NUe4
NCI-H358	M1f1dWZ2dmO2aX;uJIF{e2G7	NIW2RmQxNjYkgJtOwG0>	MUjEUXNQ	M4\xXoNifXOnczDhJINwdmO3coLlcpQh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHHu[EBGWkt?	NFS1d3ozPjl{OEW3PC=>
A549	MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYHxW\|JyhjFy4pEK{txO	NYO5SXN4TE2VTx?=	MoTuTWM2OD1yLke2JO69VQ>?	Mn3yNlY6Ojh3N{i=
NCI-H358	M2Dzemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYr+NVDjiIsQvF2=	NVz1c3lUTE2VTx?=	MlnCTWM2OD1zLkC5JO69VQ>?	Mk\INlY6Ojh3N{i=
A549	MY\BdI9xfG:\|aYOgZZN{[Xl?	M{nVRlAvPeLCit88US=>	M4\oR2ROW09?	MWHpcoR2[2W\|IFHwc5B1d3Orcx?=	NUHZTZhwOjZ7Mki1O\|g>
NCI-H358	NUHrcJljSXCxcITvd4l{KGG\|c3H5	NEjwVWExNjYkgJtOwG0>	M2HnOmROW09?	MkjlbY5lfWOnczDBdI9xfG:\|aYO=	NH\0WokzPjl{OEW3PC=>
A549	M4f5OmZ2dmO2aX;uJIF{e2G7	NVrwO4Q1OC534pEK{txO	NH\FcXdFVVOR	MUfy[YR2[2W\|IIfveY5lKGOub4P1doU>	NYr2WIlEOjZ7Mki1O\|g>
NCI-H358	MnrySpVv[3Srb36gZZN{[Xl?	NVTXc21oOC534pEK{txO	NInKeJZFVVOR	NEXHT\|hz\WS3Y3XzJJdwfW6mIHPsc5N2emV?	NVvn[WFlOjZ7Mki1O\|g>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; PubMed: 26136493 Neuro Oncol (C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.	26136493
Growth inhibition assay	Cell viability; PubMed: 30754629 Molecules Response of SK-CO-1 to various drugs and drug combinations.	30754629

In vivo

BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. ^[1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. ^[2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. ^[3]

Protocol

Kinase Assay:^[1]	- Collapse Kinase inhibition assays: The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to K_m ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:^[1]	- Collapse Cell lines: IGF-1R-Sal, RH41 and Geo cell lines Concentrations: 365 nM Incubation Time: 72 hours Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of ³H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice Dosages: 150 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BMS-754807 SDF

Molecular Weight	461.49
Formula	C₂₃H₂₄FN₉O
CAS No.	1001350-96-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Selective IGF-1R Inhibitor

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
IGF-1R Inhibitor in Clinical Trial

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
Classic IGF-1R Inhibitor

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). Picropodophyllin (PPP) induces apoptosis with antineoplastic activity.
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 (CS-0117) is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 (GSK 552602A) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
GSK1904529A

GSK1904529A (GSK 4529) is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
AG-1024

AG-1024 (Tyrphostin, AGS 200) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807